Eisai, Nobelpharma to launch anticonvulsant agent
Nobelpharma developed Fostoin in Japan. It will be marketed by Eisai and co-promoted by both companies under a previously concluded marketing agreement. Fostoin is a water-soluble prodrug of
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.